Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.


Free Access

Vis-à-Vis in the NKC: Genetically Linked Natural Killer Cell Receptor/Ligand Pairs in the Natural Killer Gene Complex (NKC)

Vogler I. · Steinle A.

Author affiliations

Institute for Molecular Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany

Corresponding Author

Dr. Alexander Steinle

Institute for Molecular Medicine, Goethe University Frankfurt am Main

Theodor-Stern-Kai 7

DE–60590 Frankfurt am Main (Germany)

Tel. +49 69 6301 3700, E-Mail Alexander.Steinle@kgu.de

Related Articles for ""

J Innate Immun 2011;3:227–235

Do you have an account?

Login Information

Contact Information

By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.

I have read the Karger Terms and Conditions and agree.


The natural killer gene complex (NKC) encodes several dozens of C-type lectin-like receptors that, in various ways, tune the reactivity of NK cells and other cytotoxic lymphocytes depending on the cellular environment. Among these are C-type lectin-like receptors such as NKG2D, CD94/NKG2A and the murine Ly49 receptors that bind to cell surface glycoproteins of the major histocompatibility complex (MHC) class I family and thereby facilitate detection of stressed cells or cells exhibiting aberrant MHC class I expression. In contrast, NKRP1 receptors including the prototypic NK1.1 do not engage ligands with an MHC class-I-like fold, but rather interact with the likewise C-type lectin-like CLEC2 glycoproteins. Notably, CLEC2 and NKRP1 molecules not only share the same fold, but are also genetically linked in the NKC. Recent research efforts began to systematically elucidate the expression and function of the numerous NKRP1 and CLEC2 family members in rodents and revealed previously unnoticed corresponding receptor/ligand pairs in humans. Here, we provide a snapshot of the current knowledge on receptors of the NKRP1 family and their genetically linked CLEC2 ligands in mouse and man.

© 2011 S. Karger AG, Basel


  1. Raulet DH, Vance RE: Self-tolerance of natural killer cells. Nat Rev Immunol 2006;6:520–531.
  2. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S: Functions of natural killer cells. Nat Immunol 2008;9:503–510.
  3. Yokoyama WM, Plougastel BF: Immune functions encoded by the natural killer gene complex. Nat Rev Immunol 2003;3:304–316.
  4. Di Santo JP: Natural killer cells: diversity in search of a niche. Nat Immunol 2008;9:473–475.
  5. Bryceson YT, Long EO: Line of attack: NK cell specificity and integration of signals. Curr Opin Immunol 2008;20:344–352.
  6. Kelley J, Walter L, Trowsdale J: Comparative genomics of natural killer cell receptor gene clusters. PLoS Genet 2005;1:129–139.
  7. Yokoyama WM, Seaman WE: The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex. Annu Rev Immunol 1993;11:613–635.
  8. Zelensky AN, Gready JE: The C-type lectin-like domain superfamily. FEBS J 2005;272:6179–6217.
  9. Hao L, Klein J, Nei M: Heterogeneous but conserved natural killer receptor gene complexes in four major orders of mammals. Proc Natl Acad Sci USA 2006;103:3192–3197.
  10. Reid DM, Gow NA, Brown GD: Pattern recognition: recent insights from Dectin-1. Curr Opin Immunol 2009;21:30–37.
  11. Llera AS, Viedma F, Sanchez-Madrid F, Tormo J: Crystal structure of the C-type lectin-like domain from the human hematopoietic cell receptor CD69. J Biol Chem 2001;276:7312–7319.
  12. Natarajan K, Sawicki MW, Margulies DH, Mariuzza RA: Crystal structure of human CD69: a C-type lectin-like activation marker of hematopoietic cells. Biochemistry 2000;39:14779–14786.
  13. Spreu J, Kienle EC, Schrage B, Steinle A: CLEC2A: a novel, alternatively spliced and skin-associated member of the NKC-encoded AICL-CD69-LLT1 family. Immunogenetics 2007;59:903–912.
  14. Iizuka K, Naidenko OV, Plougastel BF, Fremont DH, Yokoyama WM: Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat Immunol 2003;4:801–807.
  15. Glimcher L, Shen FW, Cantor H: Identification of a cell-surface antigen selectively expressed on the natural killer cell. J Exp Med 1977;145:1–9.
  16. Chambers WH, Vujanovic NL, DeLeo AB, Olszowy MW, Herberman RB, Hiserodt JC: Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med 1989;169:1373–1389.
  17. Carlyle JR, Mesci A, Ljutic B, Belanger S, Tai LH, Rousselle E, Troke AD, Proteau MF, Makrigiannis AP: Molecular and genetic basis for strain-dependent NK1.1 alloreactivity of mouse NK cells. J Immunol 2006;176:7511–7524.
  18. Arase N, Arase H, Park SY, Ohno H, Ra C, Saito T: Association with FcRgamma is essential for activation signal through NKR-P1 (CD161) in natural killer (NK) cells and NK1.1+ T cells. J Exp Med 1997;186:1957–1963.
  19. Carlyle JR, Mesci A, Fine JH, Chen P, Belanger S, Tai LH, Makrigiannis AP: Evolution of the Ly49 and Nkrp1 recognition systems. Semin Immunol 2008;20:321–330.
  20. Aust JG, Gays F, Mickiewicz KM, Buchanan E, Brooks CG: The expression and function of the NKRP1 receptor family in C57BL/6 mice. J Immunol 2009;183:106–116.
  21. Tian W, Nunez R, Cheng S, Ding Y, Tumang J, Lyddane C, Roman C, Liou HC: C-type lectin OCILRP2/Clr-g and its ligand NKRP1f costimulate T cell proliferation and IL-2 production. Cell Immunol 2005;234:39–53.
  22. Ljutic B, Carlyle JR, Filipp D, Nakagawa R, Julius M, Zuniga-Pflucker JC: Functional requirements for signaling through the stimulatory and inhibitory mouse NKR-P1 (CD161) NK cell receptors. J Immunol 2005;174:4789–4796.
  23. Carlyle JR, Jamieson AM, Gasser S, Clingan CS, Arase H, Raulet DH: Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc Natl Acad Sci USA 2004;101:3527–3532.
  24. Plougastel B, Dubbelde C, Yokoyama WM: Cloning of Clr, a new family of lectin-like genes localized between mouse Nkrp1a and Cd69. Immunogenetics 2001;53:209–214.
  25. Kartsogiannis V, Sims NA, Quinn JM, Ly C, Cipetic M, Poulton IJ, Walker EC, Saleh H, McGregor NE, Wallace ME, Smyth MJ, Martin TJ, et al: Osteoclast inhibitory lectin, an immune cell product that is required for normal bone physiology in vivo. J Biol Chem 2008;283:30850–30860.
  26. Fine JH, Chen P, Mesci A, Allan DS, Gasser S, Raulet DH, Carlyle JR: Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition. Cancer Res 2010;70:7102–7113.
  27. Voigt S, Mesci A, Ettinger J, Fine JH, Chen P, Chou W, Carlyle JR: Cytomegalovirus evasion of innate immunity by subversion of the NKR-P1B:Clr-b missing-self axis. Immunity 2007;26:617–627.
  28. Flornes LM, Nylenna O, Saether PC, Daws MR, Dissen E, Fossum S: The complete inventory of receptors encoded by the rat natural killer cell gene complex. Immunogenetics 2010;62:521–530.
  29. Kveberg L, Dai KZ, Westgaard IH, Daws MR, Fossum S, Naper C, Vaage JT: Two major groups of rat NKR-P1 receptors can be distinguished based on chromosomal localization, phylogenetic analysis and Clr ligand binding. Eur J Immunol 2009;39:541–551.
  30. Lanier LL, Chang C, Phillips JH: Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994;153:2417–2428.
  31. Iiai T, Watanabe H, Suda T, Okamoto H, Abo T, Hatakeyama K: CD161+ T (NT) cells exist predominantly in human intestinal epithelium as well as in liver. Clin Exp Immunol 2002;129:92–98.
  32. Maggi L, Santarlasci V, Capone M, Peired A, Frosali F, Crome SQ, Querci V, Fambrini M, Liotta F, Levings MK, Maggi E, Cosmi L, et al: CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol 2010;40:2174–2181.
  33. Rosen DB, Cao W, Avery DT, Tangye SG, Liu YJ, Houchins JP, Lanier LL: Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells. J Immunol 2008;180:6508–6517.
  34. Aldemir H, Prod’homme V, Dumaurier MJ, Retiere C, Poupon G, Cazareth J, Bihl F, Braud VM: Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 2005;175:7791–7795.
  35. Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL: Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 2005;175:7796–7799.
  36. Pozo D, Vales-Gomez M, Mavaddat N, Williamson SC, Chisholm SE, Reyburn H: CD161 (human NKR-P1A) signaling in NK cells involves the activation of acid sphingomyelinase. J Immunol 2006;176:2397–2406.
  37. Mathew PA, Chuang SS, Vaidya SV, Kumaresan PR, Boles KS, Pham HT: The LLT1 receptor induces IFN-gamma production by human natural killer cells. Mol Immunol 2004;40:1157–1163.
  38. Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M, Weller M: Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. Cancer Res 2007;67:3540–3544.
  39. Poggi A, Zocchi MR, Costa P, Ferrero E, Borsellino G, Placido R, Galgani S, Salvetti M, Gasperini C, Ristori G, Brosnan CF, Battistini L: IL-12-mediated NKRP1A up-regulation and consequent enhancement of endothelial transmigration of V delta 2+ TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients. J Immunol 1999;162:4349–4354.
  40. Roda-Navarro P, Arce I, Renedo M, Montgomery K, Kucherlapati R, Fernandez-Ruiz E: Human KLRF1, a novel member of the killer cell lectin-like receptor gene family: molecular characterization, genomic structure, physical mapping to the NK gene complex and expression analysis. Eur J Immunol 2000;30:568–576.
  41. Vitale M, Falco M, Castriconi R, Parolini S, Zambello R, Semenzato G, Biassoni R, Bottino C, Moretta L, Moretta A: Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol 2001;31:233–242.
  42. Welte S, Kuttruff S, Waldhauer I, Steinle A: Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol 2006;7:1334–1342.
  43. Kuttruff S, Koch S, Kelp A, Pawelec G, Rammensee HG, Steinle A: NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood 2008;113:358–369.
  44. Biassoni R, Fogli M, Cantoni C, Costa P, Conte R, Koopman G, Cafaro A, Ensoli B, Moretta A, Moretta L, De Maria A: Molecular and functional characterization of NKG2D, NKp80, and NKG2C triggering NK cell receptors in rhesus and cynomolgus macaques: monitoring of NK cell function during simian HIV infection. J Immunol 2005;174:5695–5705.
  45. Mavilio D, Benjamin J, Kim D, Lombardo G, Daucher M, Kinter A, Nies-Kraske E, Marcenaro E, Moretta A, Fauci AS: Identification of NKG2A and NKp80 as specific natural killer cell markers in rhesus and pigtailed monkeys. Blood 2005;106:1718–1725.
  46. Spreu J, Kuttruff S, Stejfova V, Dennehy KM, Schittek B, Steinle A: Interaction of C-type lectin-like receptors NKp65 and KACL facilitates dedicated immune recognition of human keratinocytes. Proc Natl Acad Sci USA 2010;107:5100–5105.
  47. Fuller GL, Williams JA, Tomlinson MG, Eble JA, Hanna SL, Pohlmann S, Suzuki-Inoue K, Ozaki Y, Watson SP, Pearce AC: The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade. J Biol Chem 2007;282:12397–12409.
  48. Dennehy KM, Klimosch SN, Steinle A: Cutting edge: NKp80 uses an atypical hemi-ITAM to trigger NK cytotoxicity. J Immunol 2011;186:657–661.
  49. Hamann J, Montgomery KT, Lau S, Kucherlapati R, van Lier RA: AICL: a new activation-induced antigen encoded by the human NK gene complex. Immunogenetics 1997;45:295–300.
  50. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A: Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62:6178–6186.
  51. Akatsuka A, Ito M, Yamauchi C, Ochiai A, Yamamoto K, Matsumoto N: Tumor cells of non-hematopoietic and hematopoietic origins express activation-induced C-type lectin, the ligand for killer cell lectin-like receptor F1. Int Immunol 2010;22:783–790.
  52. Kloss M, Decker P, Baltz KM, Baessler T, Jung G, Rammensee HG, Steinle A, Krusch M, Salih HR: Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol 2008;181:6711–6719.
  53. Thomas M, Boname JM, Field S, Nejentsev S, Salio M, Cerundolo V, Wills M, Lehner PJ: Down-regulation of NKG2D and NKp80 ligands by Kaposi’s sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci USA 2008;105:1656–1661.
  54. Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Engle XA, Rigby WF, Pioli PA, Guyre PM, Conejo-Garcia JR: PILAR is a novel modulator of human T-cell expansion. Blood 2008;112:1259–1268.
  55. Germain C, Bihl F, Zahn S, Poupon G, Dumaurier MJ, Rampanarivo HH, Berg PS, Spee P, Braud VM: Characterization of alternatively spliced transcript variants of CLEC2D gene. J Biol Chem 2010;85:36207–36215.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Review

Received: November 24, 2010
Accepted: January 06, 2011
Published online: March 22, 2011
Issue release date: April 2011

Number of Print Pages: 9
Number of Figures: 2
Number of Tables: 0

ISSN: 1662-811X (Print)
eISSN: 1662-8128 (Online)

For additional information: https://www.karger.com/JIN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.